Procter & Gamble (PG)
(Delayed Data from NYSE)
$167.31 USD
-0.33 (-0.20%)
Updated May 20, 2024 04:00 PM ET
After-Market: $167.46 +0.15 (0.09%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$167.31 USD
-0.33 (-0.20%)
Updated May 20, 2024 04:00 PM ET
After-Market: $167.46 +0.15 (0.09%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Zacks News
Here's Why Procter & Gamble (PG) Gained But Lagged the Market Today
by Zacks Equity Research
In the most recent trading session, Procter & Gamble (PG) closed at $145.94, indicating a +0.08% shift from the previous trading day.
Top 5 Consumer Staples Stocks for a Stable Portfolio in 2024
by Nalak Das
We have narrowed our search to five consumer staples stocks with strong growth potential for 2024. These are: CELH, PG, KHC, TAP, ELF.
Here's What Keeps Procter & Gamble (PG) on Growth Track
by Zacks Equity Research
Procter & Gamble (PG) looks well-placed for growth on strong demand, pricing actions, favorable mix and focus on productivity and cost-saving plans.
Procter & Gamble (PG) Stock Moves -0.07%: What You Should Know
by Zacks Equity Research
Procter & Gamble (PG) closed at $146.65 in the latest trading session, marking a -0.07% move from the prior day.
4 Stocks With Impressive Interest Coverage Ratio to Snap Up
by Sumit Singh
A company that is capable of generating earnings well above its interest expense can withstand financial hardship. EG, MOD, STRL and PG are sound enough to meet financial obligations.
Is Laird Superfood (LSF) Stock Outpacing Its Consumer Staples Peers This Year?
by Zacks Equity Research
Here is how Laird Superfood, Inc. (LSF) and Procter & Gamble (PG) have performed compared to their sector so far this year.
Brokers Suggest Investing in P&G (PG): Read This Before Placing a Bet
by Zacks Equity Research
The average brokerage recommendation (ABR) for P&G (PG) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Procter & Gamble (PG) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
Procter & Gamble (PG) reachead $153.52 at the closing of the latest trading day, reflecting a +1.58% change compared to its last close.
Procter & Gamble (PG) Laps the Stock Market: Here's Why
by Zacks Equity Research
In the most recent trading session, Procter & Gamble (PG) closed at $151.38, indicating a +0.24% shift from the previous trading day.
The Zacks Analyst Blog Highlights Intel, The Procter & Gamble, 3M, salesforce.com and Microsoft
by Zacks Equity Research
Intel, The Procter & Gamble, 3M, salesforce.com and Microsoft are part of the Zacks top Analyst Blog .
5 Top Blue-Chip Stocks to Gain From Recent Market Rally
by Nalak Das
Defying a tepid Dow, we have narrowed our search to five blue-chip (components of Dow) stocks are: MSFT, MMM, CRM, INTC, PG.
Top 5 U.S. Giants for 2024 That Have Failed to Deliver in 2023
by Nalak Das
We have narrowed our search to five U.S. corporate giants that have failed to deliver in 2023. These are: PEP, PG, MMM, XOM, GILD.
The Zacks Analyst Blog Highlights Procter & Gamble, Novartis, Mondelez International, Elevance Health and Vertex Pharmaceuticals
by Zacks Equity Research
Procter & Gamble, Novartis, Mondelez International, Elevance Health and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
Top Stock Reports for Procter & Gamble, Novartis & Mondelez International
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), Novartis AG (NVS) and Mondelez International, Inc. (MDLZ).
13F Rundown: Tepper, Buffett, Druckenmiller
by Andrew Rocco
Stock Strategist Andrew Rocco divulges valuable insights from the world's best and brightest investors.
Should You Invest in the iShares U.S. Consumer Staples ETF (IYK)?
by Zacks Equity Research
Sector ETF report for IYK
Should You Invest in the Vanguard Consumer Staples ETF (VDC)?
by Zacks Equity Research
Sector ETF report for VDC
The Zacks Analyst Blog Highlights CenterPoint Energy, NiSource, Consolidated Edison, PepsiCo and The Procter & Gamble
by Zacks Equity Research
CenterPoint Energy, NiSource, Consolidated Edison, PepsiCo and The Procter & Gamble are part of the Zacks top Analyst Blog.
Are Consumer Staples Stocks Lagging Monster Beverage (MNST) This Year?
by Zacks Equity Research
Here is how Monster Beverage (MNST) and Procter & Gamble (PG) have performed compared to their sector so far this year.
COTY Declares Share Repurchase Authorization Worth $600M
by Zacks Equity Research
COTY approves a share repurchase program worth $600 million, bringing the total share repurchase authority close to a substantial $1 billion.
5 Safe Stocks to Buy Amid Plummeting Consumer Sentiment
by Ritujay Ghosh
Consumer sentiment is declining and markets are volatile. Hence, investing in defensive stocks like CenterPoint Energy, Inc. (CNP), NiSource Inc. (NI), Consolidated Edison, Inc. (ED) PepsiCo, Inc. (PEP), and The Procter & Gamble Company (PG) will be a wise idea.
Wall Street Bulls Look Optimistic About P&G (PG): Should You Buy?
by Zacks Equity Research
The average brokerage recommendation (ABR) for P&G (PG) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Should You Invest in the Fidelity MSCI Consumer Staples Index ETF (FSTA)?
by Zacks Equity Research
Sector ETF report for FSTA
Church & Dwight (CHD) Beats Q3 Earnings Estimate, Ups Sales View
by Zacks Equity Research
Church & Dwight's (CHD) third-quarter 2023 results reflect lower earnings while sales increase year over year. Management pulls up 2023 top-line guidance.
Pricing Aids Clorox's (CLX) Q1 Earnings Amid Cyberattack Woes
by Zacks Equity Research
Clorox's (CLX) Q1 results reflect the impacts of lower volume due to the recent cyberattack. However, results are largely offset by its pricing actions and cost-saving initiatives.